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With the introduction of laparoscopic cholecystectomy 
in the late 1980’s, the endoscopic revolution was launched 
and the world of surgery changed forever.  Over the years, 
minimally invasive surgery, namely operative laparoscopy, has 
emerged as the standard treatment for many gynecologic 
benign and malignant etiologies.  Laparoscopic surgery has 
answered the patient’s right to better cosmesis, less blood 
loss, faster recovery, shorter hospital stay, and less pain.  A 
novel development in minimally invasive surgery that is even 
less invasive than traditional laparoscopy or robotic surgery is 
laparoendoscopic single-site (LESS) surgery.  It is also known 
as single-incision laparoscopic surgery (SILS) or single-port 
access (SPA) surgery.  
Benefits of LESS include better cosmesis, improved post-
operative pain scores, and less post-operative narcotic 
use.  A recent randomized trial by Chen et al. compared 
the immediate results of patients undergoing either 
two-channel single-port laparoscopic-assisted vaginal 
hysterectomy or conventional multiport laparoscopic-assisted 
vaginal hysterectomy [1-3].  The authors concluded that 
transumbilical two-channel single-port laparoscopic-assisted 
vaginal hysterectomy significantly decreases postoperative 
pain and analgesic use.  Nevertheless, the evidence based for 
its application in gynecologic oncology still in its infancy.  In 
this month’s issue of the Journal of Gynecologic Oncology, 
two provocative manuscripts of single-site surgery in the 
setting of gynecologic malignancies are reported.  Nam et 
al. [4] report a single-institution retrospective series of seven 
women with benign and malignant gynecologic disease 
who underwent robotic single-port trans-umbilical total 
hysterectomy (R-SPH).  The authors are to be commended for 
this publication, the largest report of R-SPH in the gynecologic 
literature including a robotic single-port trans-umbilical 
radical hysterectomy.  The authors concluded that R-SPH is 
technically feasible in selected patients with gynecological 
disease, and that robotics may enhance surgical skills during 
single-port trans-umbilical hysterectomy, especially in patients 
with gynecologic cancers.
As clearly stated by Barkun et al. [5], surgical innovation is an 
important part of surgery. Its assessment is complex because 
of idiosyncrasies related to surgical practice, but necessary so 
that introduction and adoption of surgical innovations can 
derive from evidence-based principles rather than trial and error.   
The rationale to perform simple or radical hysterectomies via 
a robotic single-port 4 cm in size is unclear.  At the very least, 
before adopting a new surgical technique or innovation we 
should ask ourselves the following:  Is the innovation more 
effective? If not, is it at least equally effective, but safer? Does 
it improve the patient’s experience? Is it more cost-effective? 
or easier to perform?  The report by Nam et al. [4] does not 
address any of the above questions, and should be interpreted 
strictly as a feasibility research pilot study not a clinical standard, 
specifically for the management of gynecologic malignancies.  
Also in this issue of the Journal of Gynecologic Oncology, 
Yoon et al. [6] reported on the utilization of single-port laparo  -
scopy for the staging of a patient with a borderline ovarian 
tumor.  A critical question with new technology is the adequacy, 
safety and oncologic outcomes in gynecologic malignancies 
when compared to standard methods.  It is hard to make any 
robust evidence based conclusions on level III or uncontrolled 
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descriptive reports.  Nevertheless, a recent case series by Ma-
rocco et al. [7] from Italy, confirms the findings of Yoon et al. 
[6] on the feasibility of laparoscopic fertility-sparing staging of 
borderline ovarian tumors using LESS.  The authors concluded 
that LESS staging of borderline ovarian tumors with preserva-
tion of fertility is feasible and effective with standard laparo-
scopic instruments.  
In summary, more clinical data is needed to confirm putative 
advantages of single-site surgery in gynecologic oncology when 
compared with standard multi-access laparoscopic or robotic 
techniques. Although promising, single-port robotic surgery 
remains experimental and currently a topic of much debate 
and surgical research. Technology assessment, a robust disci-
pline in medicine and health policy is essential in the field of 
surgical innovation. There should be a strict evidence-based 
progression from pre-clinical (animal/cadaver) early feasibility 
studies to subsequent clinical practice [8]. I congratulate both 
authors for their innovative work and research in this pro  mi-
sing topic of minimally invasive surgery, and look forward to 
rigorous clinical trials in this area.
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